The association of financial difficulties with clinical outcomes in cancer patients: Secondary analysis of 16 academic prospective clinical trials conducted in Italy

Annals of Oncology

Volumn 27, Issue 12, 2016, Pages 2224-2229

  Perrone, F ^a   Jommi, C ^b,h   Di Maio, M ^a,i   Gimigliano, A ^a   Gridelli, C ^c   Pignata, S ^a   Ciardiello, F ^d   Nuzzo, F ^a   de Matteis, A ^a   Del Mastro, L ^e   Bryce, J ^a   Daniele, G ^a   Morabito, A ^f   Piccirillo, M C ^a   Rocco, G ^a   Guizzaro, L ^d,g   Gallo, C ^d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c S G MOSCATI HOSPITAL   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f Departments of Thoracic Medical Oncology   (Italy)

^g EUROPEAN MEDICINES AGENCY   (United Kingdom)

^h BOCCONI UNIVERSITY   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

Author keywords

Financial toxicity; Overall survival; Public health system; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

AGE; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG COST; FINANCIAL DEFICIT; FINANCIAL MANAGEMENT; GENDER; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HIGH RISK PATIENT; HUMAN; ITALY; LUNG CANCER; MALIGNANT NEOPLASM; MULTICENTER STUDY (TOPIC); OVARY CANCER; PREDICTION; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; QUESTIONNAIRE; RISK MANAGEMENT; SCORING SYSTEM; SENSITIVITY ANALYSIS; AGED; BREAST TUMOR; ECONOMICS; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; OVARY TUMOR; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL;

AGED; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; ITALY; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 85009882020     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw433     Document Type: Article

References (19)

1. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol 2015; 1: 539-540.
2. Saltz LB. Perspectives on cost and value in cancer care. JAMA Oncol 2016; 2: 19-21.
3. Ramsey S, Blough D, Kirchhoff A et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff 2013; 32: 1143-1152.
4. Chino F, Peppercorn J, Taylor DH, Jr et al. Self-reported financial burden and satisfaction with care among patients with cancer. Oncologist 2014; 19: 414-420.
5. Zafar SY, Peppercorn JM, Schrag D et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 2013; 18: 381-390.
6. Delgado-Guay M, Ferrer J, Rieber AG et al. Financial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients. Oncologist 2015; 20: 1092-1098.
7. Lathan CS, Cronin A, Tucker-Seeley R et al. Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer. J Clin Oncol 2016; 34: 1732-1740.
8. Zafar SY, McNeil RB, Thomas CM et al. Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. J Oncol Pract 2015; 11: 145-150.
9. Ramsey SD, Bansal A, Fedorenko CR et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 2016; 34: 980-986.
10. Khera N. Reporting and grading financial toxicity. J Clin Oncol 2014; 32: 3337-3338.
11. de Souza JA, Yap B, Ratain MJ, Daugherty C. User beware: we need more science and less art when measuring financial toxicity in oncology. J Clin Oncol 2015; 33: 1414-1415.
12. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
13. Fayers PM, Aaronson NK, Bjordal K et al., on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). Brussels: European Organisation for Research and Treatment of Cancer, 2001.
14. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-144.
15. Seshamani M, Gray AM. A longitudinal study of the effects of age and time to death on hospital costs. J Health Econ 2004; 23: 217-235.
16. Sharrocks K, Spicer J, Camidge DR, Papa S. The impact of socioeconomic status on access to cancer clinical trials. Br J Cancer 2014; 111: 1684-1687.
17. Maione P, Perrone F, Gallo C et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced nonsmall-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 2005; 23: 6865-6872.
18. de Souza JA, Yap BJ, Hlubocky FJ et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer 2014; 120: 3245-3253.
19. Scott F, Huntington BMW, Dan T et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol 2015; 2: e408-e416.